Monday 21 July 2014

Anti-Amyloid Drug Has Mixed Results

COPENHAGEN (MedPage Today) -- The amyloid plaque-busting drug crenezumab for Alzheimer's disease slowed cognitive decline in patients with mild baseline impairment but missed its primary endpoint in a phase II trial. via MedPageToday.com - medical news plus CME for physicians Read More Here..

No comments:

Post a Comment